Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss
- PMID: 10048900
- DOI: 10.1097/00042560-199902010-00005
Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss
Abstract
Serum testosterone concentrations are frequently in the low-normal range (lowest quartile, <500 ng/dl) in men with AIDS-wasting syndrome (AWS) and in other chronic wasting disorders. The response of patients in this group to androgen treatment has not been determined, however. Eighteen men with AWS (mean +/- standard error [SE]: 87% +/- 1% usual body weight; CD4 count 90 +/- 24) and borderline low serum testosterone concentrations (382 +/- 33 ng/dl) completed a 21-day placebo-controlled inpatient metabolic ward study comparing intramuscular (i.m.) placebo (n = 7) with low-dose (65 mg/week; n = 4) and high-dose (200 mg/week; n = 7) nandrolone decanoate, a testosterone analogue. Nitrogen balance, stable isotope-mass spectrometric measurement of de novo lipogenesis (DNL), resting energy expenditure, and gonadal hormone levels were measured. Both low-dose and high-dose nandrolone resulted in significant nitrogen retention (33-52 g nitrogen/14 days, representing gains of 0.5 to 0.9 kg lean tissue/week) compared with placebo (loss of 11 g nitrogen/week). This was reflected biochemically in a borderline significant reduction of high DNL (p < .06). Serum testosterone and gonadotropins were suppressed whereas resting energy expenditure was unchanged by nandrolone treatment. In 10 study subjects completing a 12-week open-label follow-up phase, body weight increased by 4.9 +/- 1.2 kg, including 3.1 +/- 0.5 kg lean body mass, and treadmill exercise performance also improved. In summary, nandrolone decanoate therapy in the absence of an exercise program in borderline hypogonadal men with AWS caused substantial nitrogen retention compared with placebo, similar in extent to the nitrogen retention previously achieved with recombinant growth hormone. It is reasonable to expand the criteria for androgen treatment in AWS to include at least patients in the lowest quartile of serum testosterone.
Similar articles
-
Monitoring changes in fat-free mass in HIV-positive men with hypotestosteronemia and AIDS wasting syndrome treated with gonadal hormone replacement therapy.AIDS. 1999 Feb 4;13(2):241-8. doi: 10.1097/00002030-199902040-00012. AIDS. 1999. PMID: 10202830 Clinical Trial.
-
Therapeutic effects of nandrolone and testosterone in adult male HIV patients with AIDS wasting syndrome (AWS): a randomized, double-blind, placebo-controlled trial.HIV Clin Trials. 2010 Jul-Aug;11(4):220-9. doi: 10.1310/hct1104-220. HIV Clin Trials. 2010. PMID: 20974577 Clinical Trial.
-
Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting.J Clin Endocrinol Metab. 1996 Nov;81(11):4051-8. doi: 10.1210/jcem.81.11.8923860. J Clin Endocrinol Metab. 1996. PMID: 8923860
-
Anabolic steroids in COPD: a review and preliminary results of a randomized trial.Chron Respir Dis. 2008;5(3):169-76. doi: 10.1177/1479972308092350. Chron Respir Dis. 2008. PMID: 18684793 Review.
-
Use of androgens in patients who have HIV/AIDS: what we know about the effect of androgens on wasting and lipodystrophy.AIDS Read. 2001 Mar;11(3):149-56. AIDS Read. 2001. PMID: 17004352 Review.
Cited by
-
Anabolic steroids for the treatment of weight loss in HIV-infected individuals.Cochrane Database Syst Rev. 2005 Oct 19;2005(4):CD005483. doi: 10.1002/14651858.CD005483. Cochrane Database Syst Rev. 2005. PMID: 16235407 Free PMC article.
-
Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones.J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):287-96. doi: 10.1007/s13539-014-0152-z. Epub 2014 Aug 1. J Cachexia Sarcopenia Muscle. 2014. PMID: 25081949 Free PMC article.
-
Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels.JAMA. 2000 Feb 9;283(6):763-70. doi: 10.1001/jama.283.6.763. JAMA. 2000. PMID: 10683055 Free PMC article. Clinical Trial.
-
Use of high-dose nandrolone aggravates septic shock in a mouse model.Kaohsiung J Med Sci. 2011 Jun;27(6):222-9. doi: 10.1016/j.kjms.2010.12.015. Epub 2011 Mar 31. Kaohsiung J Med Sci. 2011. PMID: 21601167 Free PMC article.
-
Regulation of body composition by androgens.J Endocrinol Invest. 2003 Sep;26(9):814-22. doi: 10.1007/BF03345230. J Endocrinol Invest. 2003. PMID: 14964432 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials